4.10.10.4Vertical
Inflammatory Bowel Disease Centers
Specialized GI centers focused on Crohn's disease and ulcerative colitis.
Market snapshot
These figures describe Gastroenterology (4.10.10), the segment that Inflammatory Bowel Disease Centers sits within — not Inflammatory Bowel Disease Centers on its own.
FragmentationConsolidatingEstimate
Within Offices of Physicians (NAICS 621111); the Census Bureau does not split physician offices by specialty, so gastroenterology is not separately sized.
Business model & economics
Revenue model
Office visits plus high-margin endoscopy and ASC ancillaries
Key economics
- Recurring revenue
- Moderate
- EBITDA margin
- 20–30% with ancillaries
- Capex intensity
- Moderate
procedure- and screening-driven
Characteristics
- Among the hottest specialty roll-ups.
- Endoscopy and ASC ancillaries drive economics.
- Colorectal screening and aging support demand.
M&A deal context
Deal activityHigh
Who’s acquiring
- PE-backed GI platforms
- Specialty MSO consolidators
- ASC-aligned acquirers
What’s driving deals
- Rapid GI roll-up for endoscopy/ASC ancillaries.
- Screening-volume and aging demand.
- Ancillary-driven economics.
Find Inflammatory Bowel Disease Centers acquisition targets
Search Acquisera’s index for companies classified under Inflammatory Bowel Disease Centers (4.10.10.4) and build a targeted deal pipeline.
Search companies